Vericel (NASDAQ:VCEL) Insider Sells 10,000 Shares of Stock

Vericel Corporation (NASDAQ:VCEL) insider Jonathan Mark Hopper sold 10,000 shares of Vericel stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $45.00, for a total value of $450,000.00. Following the completion of the transaction, the insider owned 75,753 shares of the company’s stock, valued at approximately $3,408,885. This trade represents a 11.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Jonathan Mark Hopper also recently made the following trade(s):

• On Thursday, April 2nd, Jonathan Mark Hopper sold 3,472 shares of Vericel stock. The shares were sold at an average price of $35.00, for a total transaction of $121,520.00.

Vericel Trading Down 1.3%

Shares of VCEL stock traded down $0.58 on Tuesday, reaching $44.49. 743,265 shares of the company’s stock were exchanged, compared to its average volume of 621,141. The company’s fifty day simple moving average is $36.33 and its 200 day simple moving average is $35.85. The stock has a market capitalization of $2.27 billion, a PE ratio of 105.93 and a beta of 1.12. Vericel Corporation has a 52 week low of $28.95 and a 52 week high of $46.62.

Vericel (NASDAQ:VCEL) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.03. The company had revenue of $68.43 million for the quarter, compared to the consensus estimate of $63.68 million. Vericel had a return on equity of 6.41% and a net margin of 7.35%.Vericel’s quarterly revenue was up 30.1% on a year-over-year basis. During the same period last year, the business posted ($0.23) EPS. As a group, sell-side analysts predict that Vericel Corporation will post 0.49 earnings per share for the current fiscal year.

Institutional Trading of Vericel

Institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of Vericel by 1.9% during the 4th quarter. Vanguard Group Inc. now owns 3,584,006 shares of the biotechnology company’s stock valued at $129,060,000 after buying an additional 68,368 shares in the last quarter. State Street Corp boosted its stake in Vericel by 12.7% during the 4th quarter. State Street Corp now owns 3,163,922 shares of the biotechnology company’s stock worth $113,933,000 after purchasing an additional 356,680 shares during the last quarter. Conestoga Capital Advisors LLC boosted its position in Vericel by 9.3% during the first quarter. Conestoga Capital Advisors LLC now owns 2,463,312 shares of the biotechnology company’s stock worth $79,245,000 after acquiring an additional 208,750 shares during the last quarter. William Blair Investment Management LLC grew its position in shares of Vericel by 0.5% in the fourth quarter. William Blair Investment Management LLC now owns 2,222,107 shares of the biotechnology company’s stock valued at $80,018,000 after purchasing an additional 11,178 shares in the last quarter. Finally, Geneva Capital Management LLC grew its holdings in Vericel by 9.0% in the 3rd quarter. Geneva Capital Management LLC now owns 1,946,305 shares of the biotechnology company’s stock valued at $61,250,000 after buying an additional 161,378 shares in the last quarter.

Analyst Ratings Changes

Several research analysts recently commented on VCEL shares. Leerink Partners reiterated an “outperform” rating and set a $46.00 price objective on shares of Vericel in a research note on Tuesday, March 10th. Weiss Ratings raised Vericel from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 16th. Wall Street Zen cut Vericel from a “buy” rating to a “hold” rating in a research report on Sunday, June 14th. HC Wainwright reiterated a “buy” rating and issued a $64.00 price target on shares of Vericel in a research note on Friday, May 8th. Finally, Truist Financial cut their price target on shares of Vericel from $48.00 to $42.00 and set a “buy” rating on the stock in a research note on Wednesday, April 15th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $52.50.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.